Table 1

Characteristics associated with the JAK2V617F mutation in 241 patients with Budd-Chiari syndrome or portal vein thrombosis

All patientsWithout JAK2V617F, n = 147 (median [Q1-Q3])With JAK2V617F, n = 94 (median [Q1-Q3])P
Age, y 44 [35-59.7] 47 [35.2-58] .78 
Males, % 76 (51.7%) 36 (38.3%) .048 
Hemoglobin, g/dL 13 [11.3-14.4] 13.75 [12.3-15.1] .012 
Hematocrit, % 39 [33.8-44] 43 [38.7-47] <.001 
MCV, fL 87.3 [82.9-91.3] 85 [81-88] .023 
WBC count, ×109/L 5.7 [4.3-7.6] 8.52 [5.9-11.5] <.001 
ANC, ×109/L 3.67 [2.7-4.9] 5.25 [3.7-9] <.001 
Platelet count, ×109/L 159 [104-257] 333.5 [239-456] <.001 
Spleen size BCM, cm 0 [0-2.25] 5 [0-11.25] <.001 
Serum EPO, mU/mL 16.2 [10.6-35] 12 [7.4-17.] .002 
Measured RCM, mL/kg 26.2 [23-31] 32.9 [27-37.1] <.001 
Predicted RCM, (mL/kg 24.7 [22-26.3] 24.81 [23-27.4] .37 
RCM more than 125% of predicted 11/59 (18.6%) 38/62 (61.3%) <.001 
All patientsWithout JAK2V617F, n = 147 (median [Q1-Q3])With JAK2V617F, n = 94 (median [Q1-Q3])P
Age, y 44 [35-59.7] 47 [35.2-58] .78 
Males, % 76 (51.7%) 36 (38.3%) .048 
Hemoglobin, g/dL 13 [11.3-14.4] 13.75 [12.3-15.1] .012 
Hematocrit, % 39 [33.8-44] 43 [38.7-47] <.001 
MCV, fL 87.3 [82.9-91.3] 85 [81-88] .023 
WBC count, ×109/L 5.7 [4.3-7.6] 8.52 [5.9-11.5] <.001 
ANC, ×109/L 3.67 [2.7-4.9] 5.25 [3.7-9] <.001 
Platelet count, ×109/L 159 [104-257] 333.5 [239-456] <.001 
Spleen size BCM, cm 0 [0-2.25] 5 [0-11.25] <.001 
Serum EPO, mU/mL 16.2 [10.6-35] 12 [7.4-17.] .002 
Measured RCM, mL/kg 26.2 [23-31] 32.9 [27-37.1] <.001 
Predicted RCM, (mL/kg 24.7 [22-26.3] 24.81 [23-27.4] .37 
RCM more than 125% of predicted 11/59 (18.6%) 38/62 (61.3%) <.001 

Q1, first quartile; Q3, third quartile; MCV, mean cell volume; WBC, white blood cell; ANC, absolute neutrophil count; BCM, below costal margin; and RCM, red cell mass.

Close Modal

or Create an Account

Close Modal
Close Modal